Evonik is one of the world’s leading specialty chemicals companies. Our Health Care business serves as an innovation hub to the world’s leading pharmaceutical, medical device and nutraceutical companies. With the help of our global production network, we provide solutions to support customers along the entire value chain, from early development to commercial production. By partnering with Evonik and leveraging our portfolio of non-animal-derived amino acids, cQrex® peptides, carbohydrates and cholesterol, biopharmaceutical companies can source a range of high-purity cell culture ingredients manufactured to a consistently high level of quality at trusted, Western-based facilities. Our broad, flexible portfolio of cQrex® peptides are designed to overcome a range of solubility and stability limitations for amino acids, and are now well established for commercial use across the global cell culture industry.
In addition to the manufacturing and supply of these high-quality performance boosters, we provide customers worldwide with a range of regulatory, screening and formulation services to further enhance the value of their cell culture media.
Adeno-associated virus (AAV) vectors are a platform technology for gene therapies. Prominent examples authorized for marketing in Europe and the U.S. include Luxturna® and Zolgensma® which are based on AAV2 and AAV9 respectively. For AAV ... Continued
In this guest article, Dr. Martin Schilling of Evonik Health Care talks to Professor Michael Betenbaugh of Johns Hopkins University about the most exciting advances in cell culture, collaboration between industry and academia, and future trends....Continued
Like a cell culture connoisseur, the right selection of chemically defined ingredients enables biopharmaceutical companies to realize substantial process improvements to help prolong longevity, solubilize critical constituents and better manage the concentration of essential nutrients in cell culture. Such ingredients can optimize consistency, reduce risk and boost productivity....Continued